UROLOGIC MALIGNANCIES IN PATIENTS WITH KIDNEY TRANSPLANT
Authors:
J. Pacovsky; P. Navrátil; M. Broďák; L. Holub; J. Košina; P. Hušek
Authors‘ workplace:
Urologická klinika, FN a LF UK v Hradci Králové
Published in:
Urol List 2009; 7(1): 49-54
Overview
This paper offers an overview on a tumor pathogenesis in patients after organ transplantations. The urologic malignancies represent common tumor complications occurring in the patients after transplantations, with kidney tumors having the highest incidence. The authors of this article present general recommendations for screening malignancies and therapeutic approaches. The care about patients with tumor after the transplantation requires interdisciplinary and often individualized approach in specialized centers.
KEY WORDS:
transplantation, urologic malignancies, complication
Sources
1. Viklický O. Malignity po transplantaci ledviny. In: Transplantace ledviny v klinické praxi. Praha: Grada 2008:. 314–320.
2. Robson R, Cecka JM, Opelz G et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954–2960.
3. Sahadevan M, Kasiske BL. Long-term posttransplant management and complications. In: Danovitch GM. Handbook of kidney transplantation. 4. ed. Philadelphia: Lipincott Wiliams & Wilkins 2005: 240–241.
4. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905–913.
5. Baccarani U, Adani GL, Montanaro D et al. De novo malignancies after kidney and liver transplantation: experience on 582 consecutive cases. Transplant Proc 2006; 38: 1135–1137.
6. Saigal S, Norris S, Muiesan P et al. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002; 8: 482–487.
7. Nalesnik MA. Tumors and solid organ transplantation: intersections at multiple levels. Medscape Transplantation 2003; www.medscape.com.
8. Navarro MD, Lopez-Andreu M, Rodriguez-Benot A et al. Cancer incidence and survival in kidney transplant patients. Transplant Proc 2008; 40: 2936–2940.
9. Veroux M, Puliatti C, Fiamingo P et al. Early de novo malignancies after kidney transplantation. Transplant Proc 2004; 36: 718–720.
10. Feng S, Buell JF, Cherikh WS et al. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation 2002; 74(12): 1657–1663.
11. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplantation 1997; 2: 14–17.
12. Kaufman HM. Malignancies in organ transplant recipients. J Surg Oncol 2006; 94: 431–433.
13. Kahan BD, Ponticelli C, Campise M. Selection and preparation of the recipient. In: Principles and practise of renal transplantation. Londýn: Martin Dunitz Ltd 2000: 89–143.
14. Navrátil P. Praktická urologie u nemocných v dialyzační léčbě, před a po transplantaci ledviny. Hradec Králové: Olga Čermáková 2005: 171.
15. Kahan BD, Ponticelli C, Montagnino G. Malignancy. In: Principles and practise of renal transplantation. Londýn: Martin Dunitz Ltd 2000: 617–642.
16. Seeliger H, Guba M, Kleespies A et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases and angiogenesis. Cancer metastass reviews 2007; 26(3–4): 397.
17. Sanchez-Fructuoso A, Conesa J, Perez Florez I et al. Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 2006; 38: 2451–2452.
18. Nägele H, Bahlo M, Klabdor R et al. Tumor marker determination after orthotopic heart transplantation. J Heart Lung Transplant 1999; 18(10): 957–962.
19. Zhou M, Zhu Y, Wang L et al. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases. Clin Transpl 2006; 395–398.
20. Besarani D, Cranston D. Urological malignancy after renal transplantation. BJU Int 2007; 100: 502–505.
21. Fischereder M, Kretzler M. New immunosuppresive strategies in renal transplant recipients. J Nephrol 2004; 17: 9–18.
22. Gutierrez-Dalmau A, Campistol JM. Immunosuppresive therapy and malignancy in organ transplant recipients: A systematic review. Drugs 2007; 67(8): 1167–1198.
23. Webster A, Playford E, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166–176.
24. Dwomoa A, Cockwell P, Ives NJ et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789–791.
25. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80(2S): 254–264.
26. Rostaing L. Acute renal failure in kidney transplant patients treated with interferon alpha 2 for chronic hepatitis C. Nephron 1996; 74: 512–516.
27. Weimar W, Schellekens H, Lameijer LDF et al. Double-blind study of interferon administration in renal transplant recipients. Euro J Clin investigation 2003: 217–219.
28. Holub L, Pacovský J, Navrátil P et al. Multifokální konvenční světlobuněčný karcinom v transplantované ledvině. Urolog pro praxi 2008; 9(2): 89–90.
29. Wu MJ, Lian JD, Yang CR et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004; 43: 1091–1097.
30. Liao CH, Chueh SC, Lai MK et al. J. Transitional cell carcinoma in renal transplant recipients. Transplant Proc 2004; 36: 2152–2153.
31. Li XB, Xing NZ, Wang Y et al. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 2008; 15: 53–57.
32. Pirenne J. Treatment of bladder cancer in renal transplant recipient? Medscape Transplantation 2001; www.medscape.com.
33. Bastos M. BCG vaccine in a kidney transplant recipient? Medscape Transplantation 2006; www. medscape.com.
34. Goldberg ID, Garnick MB, Bloomer WD. Urinary tract toxic effect of cancer therapy. J Urol 1984; 132: 1–8.
35. Kleinclauss F, Gigante M, Neuzillet Y et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant 2008; 23(7): 2374–2380.
36. Campagnari JC, Ribeiro LA, Campagnari M et al. Localized prostatic cancer in patients submitted to renal transplant. International Braz J Urol 2002; 28: 330–334.
37. Antonopoulos I, Nahlas W, Piovesan R et al. Radical retropubic prostatectomy for localized prostate cancer in renal transplant patients. Urology 2007; 72: 1362–1365.
38. Hafron J, Fogarty JD, Wiesen A et al. Surgery for localized prostate cancer after renal transplantation. BJU International 2005; 95: 319–322.
39. Villalona-Calero MA, Ducker T, Holasek M et al. Mangement of testicular seminoma following organ transplantation. Med Ped Oncology 1992; 25: 242–247.
40. Abbas Y. Management of immunosuppression in a kidney transplant recipient with testicular cancer. Medscape Transplantation 2006; www.medscape.com.
41. Adu D, Cockwell P, Ives NJ et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 12: 789–792.
42. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Safety 2000; 23: 101–113.
43. Wang Z, Zhou J, Fan J et al. Sirolimus inhibits the growth and metastatic pregression of hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 11: 201–204.
44. Schuetze SM, Baker LH, Maki RG. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. J Clin Oncol 2006; 24: 18 s.
45. Buzzeo B, Hiesey D, Messing E. Bladder cancer in renal transplant recipients. Urology 1997; 50: 525–528.
46. Gruessner R, Tzardis P, Matas A et al. Ileal and colon conduits in renal transplantation. Clic Transplantation 1990; 4: 125–128.
47. Richman P, Malavaud B, Bitker MO et al. Results of 51 renal transplants with the use of bowel conduits in patients with impared bladder function: a retrospective multicenter study. Transplant Proc 1995; 27: 2427–2429.
48. Kessler M. Excess risk of cancer in renal transplant patients. Transplant Int 2006; 19: 908–914.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2009 Issue 1
Most read in this issue
- UROLOGICAL COMPLICATIONS AFTER KIDNEY TRANSPLANTATION
- SURGICAL TECHNIQUES IN KIDNEY TRANSPLANTATION
- UROLOGICAL DISEASES CONTRIBUTING TO RENAL INSUFFICIENCY AND POSSIBLE WAYS OF END STAGE RENAL DISEASE PREVENTION
- THREE KINDS OF RESOURCES FOR KIDNEY TRANSPLANTATION